Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) after Frontline Therapy with Hyper-CVAD Regimens.

被引：0
|
作者：
Thomas, Deborah A.
O'Brien, Susan [1 ]
Rytting, Michael
Faderl, Stefan
Cortes, Jorge
Wierda, William G.
Ravandi, Farhad [1 ]
Kantarjian, Hagop M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：674 / 674
页数：1
相关论文
共 50 条
  • [1] Outcome after Frontline Therapy with the Modified Hyper-CVAD Regimen with or without Rituximab for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lvmphoma (LL).
    Thomas, Deborah A.
    Kantarjian, Hagop
    Faderl, Stefan
    Wierda, William G.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Cortes, Jorge
    Koller, Charles A.
    Borthakur, Gautam
    Estrov, Zeev
    Konopleva, Marina
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    O'Brien, Susan
    BLOOD, 2008, 112 (11) : 674 - 674
  • [2] Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
    Thomas, DA
    O'Brien, S
    Cortes, J
    Giles, FJ
    Fadert, S
    Verstovsek, S
    Ferrajoli, A
    Koller, C
    Beran, M
    Pierce, S
    Ha, CS
    Cabanillas, F
    Keating, MJ
    Kantarjian, H
    BLOOD, 2004, 104 (06) : 1624 - 1630
  • [3] Favorable outcome with hyper-CVAD in lymphoblastic lymphoma (LL).
    Thomas, DA
    Cortes, J
    O'Brien, SM
    Giles, F
    Faderl, S
    Verstovsek, S
    Ferrajoli, A
    Beran, M
    Cabanillas, F
    Kantarjian, H
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 581S - 581S
  • [4] Improved outcome with the hyper-CVAD regimen in lymphoblastic lymphoma (LL).
    Thomas, DA
    Cortes, J
    O'Brien, SM
    Giles, FJ
    Faderl, S
    Cabanillas, F
    Murphy, SB
    Kantarjian, HM
    BLOOD, 2000, 96 (11) : 833A - 833A
  • [5] Update of the modified hyper-CVAD regimen with or without rituximab as frontline therapy of adults with acute lymphocytic leukemia (ALL) or lymphoblastic lymphoma (ILL)
    Thomas, Deborah A.
    Kantarjian, Hagop
    Faderl, Stefan
    Koller, Charles
    Ravandi-Kashani, Farhad
    Beran, Miloslav
    O'Brien, Susan
    BLOOD, 2007, 110 (11) : 831A - 831A
  • [6] Long-Term Outcome for De Novo Lymphoblastic Lymphoma (LL) After Frontline Therapy with Hyper-CVAD Regimen and Variants
    Thomas, Deborah A.
    Faderl, Stefan
    O'Brien, Susan
    Wierda, William G.
    Garcia-Manero, Guillermo
    Verstovsek, Srdan
    Konopleva, Marina
    Kadia, Tapan
    Kornblau, Steven M.
    Fayad, Luis
    Romaguera, Jorge
    Cortes, Jorge T.
    Kantarjian, Hagop
    BLOOD, 2010, 116 (21) : 1167 - 1168
  • [7] Outcome for Adolescents and Young Adults (AYA) with the Hyper-CVAD (with or without Rituximab) Regimens for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.
    Thomas, Deborah A.
    Rytting, Michael
    O'Brien, Susan
    Faderl, Stefan
    Wierda, William G.
    Franklin, Anna
    Garris, Rebecca
    Ravandi, Farhad
    Cortes, Jorge
    Kantarjian, Hagop M.
    BLOOD, 2009, 114 (22) : 1199 - 1199
  • [8] Role of Allogeneic HCT as Postremission Therapy for Transplant-Eligible Adult Lymphoblastic Leukemia/Lymphoma After Frontline Hyper-CVAD
    Damlaj, Moussab
    Snnallah, Mohammad
    Bashir, Razan
    Eddine, Inaam Shehab
    Alahmari, Bader
    Salama, Hind
    Alaskar, Ahmed
    Alhejazi, Ayman
    Alzahrani, Mohsen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 (10): : 690 - 696
  • [9] Phase II Study of Nelarabine with Hyper-CVAD in Patients with Previously Untreated T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (LL)
    Jain, Preetesh
    Kantarjian, Hagop M.
    Thomas, Deborah A.
    Ravandi, Farhad
    Kadia, Tapan M.
    Burger, Jan A.
    Borthakur, Gautam
    Cortes, Jorge E.
    Daver, Naval
    Jabbour, Elias J.
    Koller, Charles Asa
    Konopleva, Marina
    Pemmaraju, Naveen
    Kelly, Marry A.
    Garris, Rebecca
    O'Brien, Susan
    Faderl, Stefan
    BLOOD, 2012, 120 (21)
  • [10] Phase II study of hyper-CVAD followed by nelarabine consolidation in newly diagnosed patients with T cell acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LL).
    Vigil, C. E.
    Kantarjian, H.
    Thomas, D. A.
    O'Brien, S. M.
    Kashani, F. Ravandi
    Koller, C. A.
    Burger, J. A.
    Garris, R. S.
    Baccus, M. D.
    Faderl, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345